Tmdx stock price saw mild volatility today after a prominent hedge fund disclosed a larger stake. Historically, such positions have preceded multi-week rallies in similar industry peers. CNBC reported that drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years. This typically includes pills and most medications. This goes hand in hand with the 13-year wait until more complex biotech drugs are eligible for Medicare price negotiations. With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey. After a brief dip last week, tmdx stock price recovered quickly to $30+, highlighting resilience amid market volatility. Sector ETFs tracking medical devices have also posted gains, reinforcing bullish sentiment.